Michael N. Pollak

Michael N. Pollak's AcademicInfluence.com Rankings

Michael N. Pollak

Medical

#912

World Rank

#1175

Historical Rank

Oncology

#29

World Rank

#30

Historical Rank

medical Degrees

Michael N. Pollak

Philosophy

#3237

World Rank

#5278

Historical Rank

Logic

#1027

World Rank

#1645

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Michael N. Pollak's Degrees

Doctorate Medicine Harvard University

Why Is Michael N. Pollak Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Michael N. Pollak's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Insulin and insulin-like growth factor signalling in neoplasia (2008) (1934)
Circulating concentrations of insulin-like growth factor I and risk of breast cancer (1998) (1864)
Insulin-like growth factors and neoplasia (2004) (1500)
Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study (1998) (1412)
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. (2006) (1058)
Metformin improves healthspan and lifespan in mice (2013) (1031)
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. (2000) (1005)
The insulin and insulin-like growth factor receptor family in neoplasia: an update (2012) (975)
Metformin: from mechanisms of action to therapies. (2014) (922)
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). (2001) (912)
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. (2007) (876)
Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. (1998) (824)
Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. (1999) (779)
mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. (2013) (606)
Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria (2014) (476)
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression (2010) (459)
Investigating metformin for cancer prevention and treatment: the end of the beginning. (2012) (452)
Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. (2001) (425)
Lifestyle correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. (2002) (422)
A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. (2000) (422)
The Type 1 Insulin-Like Growth Factor Receptor Pathway (2008) (420)
Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. (2008) (415)
Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. (2008) (398)
mTOR coordinates protein synthesis, mitochondrial activity and proliferation (2015) (360)
Obesity, Diabetes, and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial (2006) (359)
Metformin directly acts on mitochondria to alter cellular bioenergetics (2014) (343)
MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. (1985) (340)
The eEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation (2013) (338)
Elevated circulating branched chain amino acids are an early event in pancreatic adenocarcinoma development (2014) (333)
Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies (2008) (330)
A prospective study of plasma C-peptide and colorectal cancer risk in men. (2004) (324)
Re: Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer (2002) (322)
Insulin-like growth factor physiology and cancer risk. (2000) (305)
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. (2015) (305)
The Effects of Adiponectin and Metformin on Prostate and Colon Neoplasia Involve Activation of AMP-Activated Protein Kinase (2008) (294)
Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions (2009) (289)
Metformin Reduces Endogenous Reactive Oxygen Species and Associated DNA Damage (2012) (288)
Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. (1990) (283)
Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. (2003) (281)
Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. (2002) (280)
Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells (2005) (277)
The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study (2012) (271)
Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. (2002) (264)
In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. (2008) (261)
In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). (2001) (257)
Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. (2010) (245)
Estradiol and Antiestrogens Regulate a Growth Inhibitory Insulin-like Growth Factor Binding Protein 3 Autocrine Loop in Human Breast Cancer Cells (*) (1996) (241)
A Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as Risk Factors for Endometrial Cancer (2008) (238)
Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. (2001) (231)
Metformin and Other Biguanides in Oncology: Advancing the Research Agenda (2010) (229)
Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. (2009) (219)
Insulin-like growth factors and prostate cancer. (2001) (219)
A Prospective Study of C-Peptide, Insulin-like Growth Factor-I, Insulin-like Growth Factor Binding Protein-1, and the Risk of Colorectal Cancer in Women (2005) (218)
Insulin receptor expression by human prostate cancers (2009) (217)
Molecular mechanisms underlying IGF‐I‐induced attenuation of the growth‐inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells (2004) (203)
Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. (2013) (198)
Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. (2005) (197)
Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. (2001) (194)
Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells (2010) (194)
Milk intake, circulating levels of insulin-like growth factor-I, and risk of colorectal cancer in men. (2001) (193)
Circulating Levels of Insulin-like Growth Factors, their Binding Proteins, and Breast Cancer Risk (2005) (192)
Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. (2008) (191)
Association of markers of insulin and glucose control with subsequent colorectal cancer risk. (2003) (191)
Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor (2007) (188)
Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. (2007) (188)
Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo (2011) (187)
Distinct perturbation of the translatome by the antidiabetic drug metformin (2012) (186)
A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men. (2000) (186)
Systemic cancer therapy: achievements and challenges that lie ahead (2013) (186)
Insulin-like growth factors and prostate cancer: a population-based case-control study in China. (2001) (183)
Effects of Lycopene Supplementation in Patients with Localized Prostate Cancer (2002) (182)
mTOR as a central regulator of lifespan and aging (2019) (180)
Potential applications for biguanides in oncology. (2013) (172)
A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup (2018) (172)
nanoCAGE reveals 5′ UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs (2016) (171)
Soy Isoflavones in the Treatment of Prostate Cancer (2003) (169)
Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation. (1996) (166)
Presence of somatomedin receptors on primary human breast and colon carcinomas. (1987) (164)
Suramin blockade of insulinlike growth factor I-stimulated proliferation of human osteosarcoma cells. (1990) (162)
Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? (2017) (161)
High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling (2011) (160)
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. (2008) (156)
Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. (1997) (154)
Circulating IGF-I: New Perspectives for a New Century (1999) (153)
A study of high‐dose oral silybin‐phytosome followed by prostatectomy in patients with localized prostate cancer (2010) (150)
In vivo inhibition of insulin-like growth factor I gene expression by tamoxifen. (1993) (150)
Metformin and the Incidence of Prostate Cancer in Patients with Type 2 Diabetes (2010) (148)
Perspectives on clonogenic tumor cells, stem cells, and oncogenes. (1984) (146)
Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer. (2013) (144)
Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer (2015) (143)
Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. (2000) (142)
Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. (2006) (141)
Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. (2003) (136)
Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. (1993) (134)
Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c (2011) (132)
Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells (2005) (132)
Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. (2011) (130)
Are Metformin Doses Used in Murine Cancer Models Clinically Relevant? (2016) (129)
Reproducibility of Plasma Steroid Hormones, Prolactin, and Insulin-like Growth Factor Levels among Premenopausal Women over a 2- to 3-Year Period (2006) (127)
A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. (2016) (127)
IGFBP7 Binds to the IGF-1 Receptor and Blocks Its Activation by Insulin-Like Growth Factors (2012) (125)
Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. (1997) (124)
Castration-Induced Apoptosis in the Rat Ventral Prostate Is Associated with Increased Expression of Genes Encoding Insulin-Like Growth Factor Binding Proteins 2, 3, 4 and 5. (1998) (124)
IGF-1, IGFBP-1, and IGFBP-3 Polymorphisms Predict Circulating IGF Levels but Not Breast Cancer Risk: Findings from the Breast and Prostate Cancer Cohort Consortium (BPC3) (2008) (123)
Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes (2008) (123)
Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. (2000) (123)
A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity (2021) (122)
Insulin-Like Growth Factor Axis and Risk of Type 2 Diabetes in Women (2012) (120)
Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. (1999) (119)
Epidermal growth factor receptor gene-amplified MDA-468 breast cancer cell line and its nonamplified variants (1987) (117)
Exercise modulation of the host-tumor interaction in an orthotopic model of murine prostate cancer. (2012) (117)
Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. (2007) (117)
Milk consumption and the prepubertal somatotropic axis (2007) (116)
Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes (2012) (116)
Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist (2001) (115)
Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. (2002) (114)
Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. (2001) (113)
Insulin increases de novo steroidogenesis in prostate cancer cells. (2011) (112)
A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. (2013) (109)
The Insulin Receptor/Insulin-Like Growth Factor Receptor Family as a Therapeutic Target in Oncology (2012) (107)
Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index (2017) (107)
Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer (2012) (107)
Serine deprivation enhances antineoplastic activity of biguanides. (2014) (107)
Targeting insulin and insulin-like growth factor signalling in oncology. (2008) (106)
Expression of insulin‐like growth factor receptor, IGF‐1, and IGF‐2 in primary and metastatic osteosarcoma (1998) (106)
Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis (2007) (106)
Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. (1993) (106)
Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. (2009) (106)
Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. (1989) (105)
Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analog EB1089. (1998) (104)
Antiproliferative action of tumor necrosis factor-alpha on MCF-7 breastcancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation. (1998) (103)
Racial Differences in Premenopausal Endogenous Hormones (2005) (103)
Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). (2014) (101)
Prediagnostic Plasma C-Peptide and Pancreatic Cancer Risk in Men and Women (2007) (101)
The Effects of Varying Dietary Carbohydrate and Fat Content on Survival in a Murine LNCaP Prostate Cancer Xenograft Model (2009) (100)
C-Reactive Protein Concentrations and Subsequent Ovarian Cancer Risk (2007) (99)
Insulin-like Growth Factors and Prostate Cancer (2001) (98)
Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours (2005) (98)
Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target energy metabolism for cancer treatment (2014) (96)
Tumor suppressor activity of the gene encoding mammary-derived growth inhibitor. (1995) (96)
Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. (2000) (95)
Insulin, insulin-like growth factors and neoplasia. (2008) (95)
Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China. (2001) (91)
Insulinlike growth factor I: a potent mitogen for human osteogenic sarcoma. (1990) (91)
Whole milk intake is associated with prostate cancer-specific mortality among U.S. male physicians. (2013) (91)
Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. (2011) (91)
Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(alpha)anthracene-induced rat mammary carcinomas. (1994) (88)
Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults (2018) (88)
Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. (2003) (88)
Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. (2014) (87)
Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived Phosphoinositide-Dependent Kinase-1 Inhibitor (2006) (86)
Polymorphic variation at the ‐202 locus in IGFBP3: Influence on serum levels of insulin‐like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk (2003) (86)
Antiproliferative action of vitamin D-related compounds and insulin-like growth factor-binding protein 5 accumulation. (1997) (86)
Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention (1998) (85)
Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182780. (1996) (85)
Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. (2011) (85)
Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. (1992) (85)
Relevance of the OCT1 transporter to the antineoplastic effect of biguanides. (2011) (84)
Characterization of insulin-like growth factor I (IGF-I) receptors of human breast cancer cells. (1988) (82)
Genomewide meta‐analysis identifies loci associated with IGF‐I and IGFBP‐3 levels with impact on age‐related traits (2016) (82)
Serum concentrations of IGF‐I, IGFBP‐3 and c‐peptide and risk of hyperplasia and cancer of the breast in postmenopausal women (2004) (81)
The Use of Metformin and the Incidence of Lung Cancer in Patients With Type 2 Diabetes (2012) (81)
C-Peptide, Insulin-like Growth Factor Binding Protein-1, Glycosylated Hemoglobin, and the Risk of Distal Colorectal Adenoma in Women (2006) (80)
Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer (2018) (80)
Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. (2007) (80)
Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin (2013) (79)
Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. (2007) (79)
Insulin-Like Growth Factor Binding Protein-2 Is a Novel Therapeutic Target Associated with Breast Cancer (2008) (79)
Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. (2006) (78)
Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. (2002) (78)
Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. (2013) (78)
Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft. (2007) (77)
Circulating Insulin and C-Peptide Levels and Risk of Breast Cancer among Predominately Premenopausal Women (2007) (76)
A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780. (1996) (76)
Amplified, overexpressed and rearranged epidermal growth factor receptor gene in a human astrocytoma cell line. (1985) (76)
Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. (2002) (76)
Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. (2008) (75)
Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study (2007) (75)
Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms (2015) (74)
Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era (2005) (74)
Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. (1992) (73)
Insulin-like growth factor binding protein 3 (IGF-BP3) inhibits estrogen-stimulated breast cancer cell proliferation. (1994) (73)
High-Fat Diet Accelerates Carcinogenesis in a Mouse Model of Barrett's Esophagus via Interleukin 8 and Alterations to the Gut Microbiome. (2019) (73)
Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. (2009) (73)
A genome-wide association study identifies novel loci associated with circulating IGF-I and IGFBP-3. (2011) (71)
A pilot ‘window of opportunity’ neoadjuvant study of metformin in localised prostate cancer (2014) (70)
The effects of metformin on gut microbiota and the immune system as research frontiers (2017) (70)
Prediagnostic plasma IGFBP‐1, IGF‐1 and risk of prostate cancer (2015) (69)
Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. (2008) (69)
Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 Molar Ratio and Risk of Pancreatic Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (2010) (69)
Body shape throughout life and correlations with IGFs and GH. (2007) (66)
Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin (2009) (66)
Menopause Is a Determinant of Breast Aromatase Expression and Its Associations With BMI, Inflammation, and Systemic Markers (2017) (66)
Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial (2014) (66)
Insulin-like growth factor 1 (IGF-1) receptors, IGF-1, and IGF-2 are expressed in primary human sarcomas. (1995) (65)
Silencing of the mammary-derived growth inhibitor (MDGI) gene in breast neoplasms is associated with epigenetic changes. (1996) (64)
Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts (2007) (64)
Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas. (2010) (64)
Body size in early life and adult levels of insulin-like growth factor 1 and insulin-like growth factor binding protein 3. (2011) (64)
Somatic point mutations occurring early in development: a monozygotic twin study (2013) (63)
Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins. (1999) (63)
PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. (2005) (62)
The Use of Metformin and Colorectal Cancer Incidence in Patients with Type II Diabetes Mellitus (2013) (62)
Metabolic syndrome components and colorectal adenoma in the CLUE II cohort (2009) (62)
Higher circulating levels of IGF-1 are associated with longer leukocyte telomere length in healthy subjects (2009) (62)
ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway. (2011) (61)
Serum leptin and adiponectin levels and risk of renal cell carcinoma (2012) (61)
Insulin-like growth factor-related signaling and cancer development. (2007) (60)
Periprostatic adipose inflammation is associated with high-grade prostate cancer (2017) (60)
A prospective study of circulating adipokine levels and risk of multiple myeloma. (2012) (60)
Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer (2011) (60)
H19 sense and antisense transgenes modify insulin-like growth factor-II mRNA levels. (2000) (60)
A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model (2005) (59)
Plasma IGF-I levels and cognitive performance in older women (2007) (59)
Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas (1995) (59)
Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. (2010) (59)
Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and the risk of colorectal adenoma and cancer in the Nurses' Health Study. (2000) (59)
Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue. (1994) (58)
Serum insulin-like growth factor I and subsequent risk of colorectal cancer among Japanese-American men. (2003) (58)
Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA.14 adjuvant breast cancer trial. (2006) (58)
Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741 (2008) (58)
In vitro metformin antineoplastic activity in epithelial ovarian cancer (2008) (57)
Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. (1993) (56)
Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14. (2011) (56)
Hormonal profile of diabetic men and the potential link to prostate cancer (2008) (56)
Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations (2011) (56)
Translational and HIF-1α-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides. (2018) (55)
Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study (2016) (54)
Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins. (1999) (54)
Insulin, insulin-like growth factors, insulin resistance, and neoplasia. (2007) (53)
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab (2010) (53)
Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma (2012) (53)
A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. (2010) (53)
Type 2 diabetes and the risk of mortality among patients with prostate cancer (2014) (52)
Insulin analogues and cancer risk: cause for concern or cause célèbre? (2010) (52)
Targeting oxidative phosphorylation: why, when, and how. (2013) (51)
IGFBP‐2 Expression in MCF‐7 Cells is Regulated by the PI3K/AKT/mTOR Pathway through Sp1 Induced Increase in Transcription (2010) (51)
Obesity-related hormones and endometrial cancer among postmenopausal women: a nested case-control study within the B~FIT cohort. (2013) (51)
A prospective study of intakes of zinc and heme iron and colorectal cancer risk in men and women (2011) (51)
Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780. (2001) (50)
A Phase II Pharmacodynamic Study of Preoperative Figitumumab in Patients with Localized Prostate Cancer (2012) (50)
Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers. (2004) (50)
Tamoxifen reduces serum insulin-like growth factor I (IGF-I) (2005) (50)
Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy (2012) (49)
Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells. (2002) (49)
Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes (2010) (48)
Uterotrophic actions of estradiol and tamoxifen are associated with inhibition of uterine insulin-like growth factor binding protein 3 gene expression. (1994) (48)
Glycemic load effect on fasting and post-prandial serum glucose, insulin, IGF-1 and IGFBP-3 in a randomized, controlled feeding study (2012) (48)
Body size and breast cancer prognosis: a statistical explanation of the discrepancies. (1989) (47)
Circulating Leptin and Risk of Pancreatic Cancer: A Pooled Analysis From 3 Cohorts. (2015) (47)
Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitro. (1992) (46)
Effects of Rapid Weight Loss on Systemic and Adipose Tissue Inflammation and Metabolism in Obese Postmenopausal Women (2017) (46)
Effect of intermittent fasting on prostate cancer tumor growth in a mouse model (2009) (46)
Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2,3,4 and 5. (1998) (46)
Insulin-like Growth Factors and Ovarian Cancer Risk: A Nested Case-Control Study in Three Cohorts (2007) (45)
eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma (2019) (45)
Carbon source and myc expression influence the antiproliferative actions of metformin. (2012) (45)
Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. (2012) (44)
Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet. (2010) (44)
Racial Variation in Sex Steroid Hormones and the Insulin-Like Growth Factor Axis in Umbilical Cord Blood of Male Neonates (2009) (44)
IGF2 increases de novo steroidogenesis in prostate cancer cells. (2013) (44)
Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival. (2014) (44)
Protein Expression of PTEN, Insulin-Like Growth Factor I Receptor (IGF-IR), and Lethal Prostate Cancer: A Prospective Study (2013) (44)
Finasteride Modifies the Relation between Serum C-Peptide and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial (2010) (44)
Metformin, aging and cancer (2013) (43)
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab (2012) (42)
Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and prostate cancer risk: epidemiological studies. (2000) (42)
The Use of Metformin in Patients with Prostate Cancer and the Risk of Death (2014) (42)
Plasma insulin‐like growth factor 1 is positively associated with low‐grade prostate cancer in the Health Professionals Follow‐up Study 1993–2004 (2011) (41)
Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis (2010) (41)
Hypoxia‐inducible factor‐1α (HIF‐1α) gene polymorphisms, circulating insulin‐like growth factor binding protein (IGFBP)‐3 levels and prostate cancer (2007) (41)
Premenopausal levels of circulating insulin‐like growth factor I and the risk of postmenopausal breast cancer (2006) (41)
Do cancer cells care if their host is hungry? (2009) (40)
Uncoupling Hepatic Oxidative Phosphorylation Reduces Tumor Growth in Two Murine Models of Colon Cancer. (2018) (40)
Fasting Insulin Levels and Cognitive Decline in Older Women without Diabetes (2008) (39)
Prediagnostic circulating adipokine concentrations and risk of renal cell carcinoma in male smokers. (2013) (39)
IGF-I physiology and breast cancer. (1998) (39)
Metformin abolishes increased tumor 18F-2-fluoro-2-deoxy-D-glucose uptake associated with a high energy diet (2011) (38)
Genetic Variants, Prediagnostic Circulating Levels of Insulin-like Growth Factors, Insulin, and Glucose and the Risk of Colorectal Cancer: The Multiethnic Cohort Study (2012) (38)
Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression. (2004) (38)
IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias (2016) (37)
Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. (2016) (37)
The human mammary-derived growth inhibitor (MDGI) gene: genomic structure and mutation analysis in human breast tumors. (1996) (36)
Interactions between Plasma Levels of 25-Hydroxyvitamin D, Insulin-Like Growth Factor (IGF)-1 and C-Peptide with Risk of Colorectal Cancer (2011) (36)
Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer. (2004) (35)
Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer (2014) (35)
Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status. (2016) (35)
Reduced growth of human sarcoma xenografts in hosts homozygous for the lit mutation (2002) (34)
Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells. (2004) (34)
Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial (2014) (34)
A dietary pattern that is associated with C-peptide and risk of colorectal cancer in women (2011) (34)
Centralized Blood Processing for the Selenium and Vitamin E Cancer Prevention Trial: Effects of Delayed Processing on Carotenoids, Tocopherols, Insulin-Like Growth Factor-I, Insulin-Like Growth Factor Binding Protein 3, Steroid Hormones, and Lymphocyte Viability (2005) (33)
Why Cancer & Metabolism? Why now? (2013) (33)
Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer. (2016) (33)
Metformin and pancreatic cancer: a clue requiring investigation. (2012) (33)
IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer. (2011) (32)
Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease (2018) (32)
Alterations in Cellular Energy Metabolism Associated with the Antiproliferative Effects of the ATM Inhibitor KU-55933 and with Metformin (2012) (32)
Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome (2016) (32)
Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes. (2017) (32)
Loss of function of PTEN alters the relationship between glucose concentration and cell proliferation, increases glycolysis, and sensitizes cells to 2-deoxyglucose. (2010) (31)
Insulin-Like Growth Factors and Insulin-Like Growth Factor–Binding Proteins and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial (2013) (31)
Treatment with Insulin Analog X10 and IGF-1 Increases Growth of Colon Cancer Allografts (2013) (31)
Inhibition of insulin-like growth factor I receptor signaling by the vitamin D analogue EB1089 in MCF-7 breast cancer cells: A role for insulin-like growth factor binding proteins. (1999) (31)
Plasma C-Peptide, Mammographic Breast Density, and Risk of Invasive Breast Cancer (2013) (31)
Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink (2016) (31)
High insulinlike growth factor binding protein 1 level predicts incident congestive heart failure in the elderly. (2008) (31)
Serum Insulin-Like Growth Factor-I Levels and Prostatic Intraepithelial Neoplasia: A Clue to the Relationship Between IGF-I Physiology and Prostate Cancer Risk (2005) (30)
Inflammatory Plasma Markers and Pancreatic Cancer Risk: A Prospective Study of Five U.S. Cohorts (2013) (30)
The hedgehog pathway inhibitor cyclopamine increases levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells. (2007) (30)
Insulin-like growth factors and risk of kidney cancer in men (2010) (29)
Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A) (2016) (29)
5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer. (2015) (29)
Low Levels of Circulating Adiponectin Are Associated with Multiple Myeloma Risk in Overweight and Obese Individuals. (2016) (29)
The use of aspirin and the risk of mortality in patients with prostate cancer. (2015) (29)
Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, growth hormone, and mammographic density in the Nurses’ Health Studies (2012) (28)
Serum C-Reactive Protein and Risk of Pancreatic Cancer in Two Nested, Case–Control Studies (2010) (28)
Specimen processing time and measurement of total insulin-like growth factor-I (IGF-I), free IGF-I, and IGF binding protein-3 (IGFBP-3). (2006) (28)
Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study (2014) (28)
Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion. (2019) (28)
Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer. (2014) (28)
BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. (2009) (27)
Insulin-like growth factor receptor ( IGF-1 R ) in breast cancer subtypes (2012) (27)
Challenges to cancer control by screening (2003) (27)
Insulin-like growth factor physiology and neoplasia. (2000) (27)
HH2A, an immortalized bovine mammary epithelial cell line, expresses the gene encoding mammary derived growth inhibitor (MDGI) (2007) (26)
Serum insulin-like growth factor-I (IGF-I) does not correlate positively with isometric strength, fatigue, and quality of life in post-polio syndrome (2001) (26)
Dependent Translation Initiation in Breast Cancer Cells − Metformin Inhibits Mammalian Target of Rapamycin (2007) (26)
Glioma Risk in Relation to Serum Levels of Insulin-Like Growth Factors (2007) (25)
Insulin-like growth factors and leukocyte telomere length: the cardiovascular health study. (2009) (25)
Effects of castration on insulin levels and glucose tolerance in the mouse differ from those in man (2010) (25)
Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells (2016) (25)
Lycopene in the treatment of prostate cancer (2002) (25)
Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. (2007) (24)
The potential role of somatostatin analogues in breast cancer treatment. (1997) (24)
Insulin-like growth factor-1 and insulin-like growth factor binding protein-3 for prostate cancer detection in patients undergoing prostate biopsy. (2002) (23)
Fasting Plasma Insulin, C-Peptide and Cognitive Change in Older Men without Diabetes: Results from the Physicians’ Health Study II (2010) (23)
Plasma insulinlike growth factor 1 and binding-protein 3 and risk of myocardial infarction in women: a prospective study. (2008) (23)
Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgen‐independent progression (2011) (23)
Decline in circulating insulin-like growth factors and mortality in older adults: cardiovascular health study all-stars study. (2012) (23)
Insulin-like Growth Factor-I and Risk of High-Grade Cervical Intraepithelial Neoplasia (2007) (22)
Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials (2017) (22)
Risk of cancer after growth-hormone treatment (2002) (22)
Prostate Cancer Progression (2010) (22)
Effect of isocaloric low fat diet on prostate cancer xenograft progression in a hormone deprivation model. (2010) (22)
Plasma C-peptide levels and rates of cognitive decline in older, community-dwelling women without diabetes (2008) (22)
A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation (2012) (21)
Racial variation in vitamin D cord blood concentration in white and black male neonates (2012) (21)
Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin (2019) (21)
Exercise and Prostate Cancer: Evidence and Proposed Mechanisms for Disease Modification (2016) (21)
Intact and total insulin-like growth factor-binding protein-3 (IGFBP-3) levels in relation to breast cancer risk factors: a cross-sectional study (2008) (21)
Dinucleotide repeat in the insulin-like growth factor-I gene is not related to risk of colorectal adenoma. (2002) (21)
Vertex balding, plasma insulin-like growth factor 1, and insulin-like growth factor binding protein 3. (2000) (21)
Insulin-like Growth Factor Binding Protein-3 Induces Apoptosis in MCF 7 Breast Cancer Cells (1997) (21)
The human insulin-like growth factor-binding protein 4 gene maps to chromosome region 17q12-q21.1 and is close to the gene for hereditary breast-ovarian cancer. (1993) (20)
Risk of Breast Cancer by Individual Insulin Use: An International Multicenter Study (2013) (20)
Circulating Insulin-like Growth Factor (IGF)-I and IGF Binding Protein (IGFBP)-3 Levels and Postmenopausal Breast Cancer Risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort (2010) (20)
IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein. (2012) (19)
Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer (2005) (19)
Metabolic heterogeneity signature of primary treatment-naïve prostate cancer (2017) (19)
No Association between Serum Insulin-Like Growth Factor (IGF)-I, IGF-Binding Protein-3, and Lung Cancer Risk (2006) (18)
The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer (2012) (18)
Magnesium intake, plasma C-peptide, and colorectal cancer incidence in US women: a 28-year follow-up study (2012) (18)
Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease (2016) (18)
Metastatic behavior of the RIF-1 murine fibrosarcoma: inhibited by hypophysectomy and partially restored by growth hormone replacement. (1994) (18)
Plasma Levels of Acid-Labile Subunit, Free Insulin-Like Growth Factor-I, and Prostate Cancer Risk: A Prospective Study (2010) (17)
in Patients with Localized Prostate Cancer A Phase II Pharmacodynamic Study of Preoperative Figitumumab (2012) (17)
Germ line knockout of IGFBP-3 reveals influences of the gene on mammary gland neoplasia (2015) (17)
Associations of pregnancy characteristics with maternal and cord steroid hormones, angiogenic factors, and insulin-like growth factor axis (2011) (17)
Maternal and cord steroid sex hormones, angiogenic factors, and insulin-like growth factor axis in African-American preeclamptic and uncomplicated pregnancies (2012) (17)
Circulating levels of obesity-related markers and risk of renal cell carcinoma in the PLCO cancer screening trial (2017) (17)
Impact of Addition of Metformin to Abiraterone in Metastatic Castration‐Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb‐Pro): Phase 2 Pilot Study (2019) (17)
Trajectories of IGF-I Predict Mortality in Older Adults: The Cardiovascular Health Study (2018) (17)
Serum insulin‐like growth factor (IGF)‐1 and IGF‐binding protein‐3 do not correlate with Gleason score or quantity of prostate cancer in biopsy samples (2003) (17)
Quantification of binding of IGF-1 to BI 836845, a candidate therapeutic antibody against IGF-1 and IGF-2, and effects of this antibody on IGF-1:IGFBP-3 complexes in vitro and in male C57BL/6 mice. (2014) (16)
Metastatic Breast Carcinoma–Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression (2019) (16)
High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum (2016) (16)
Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial. (2009) (16)
Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study. (1991) (16)
Circulating adiponectin levels differ between patients with multiple myeloma and its precursor disease (2017) (16)
Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and lobule type in the Nurses' Health Study II (2012) (15)
A hydride transfer complex reprograms NAD metabolism and bypasses senescence. (2021) (15)
Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population (2020) (15)
Fatty acid metabolism in human breast cancer cells (MCF7) transfected with heart-type fatty acid binding protein (1999) (15)
Randomized Phase II Trial of Exercise, Metformin, or Both on Metabolic Biomarkers in Colorectal and Breast Cancer Survivors (2019) (15)
Repression of LKB1 by miR-17∼92 Sensitizes MYC-Dependent Lymphoma to Biguanide Treatment (2019) (15)
Insulinlike Growth Factor Binding Protein-1 and Ghrelin Predict Health Outcomes Among Older Adults: Cardiovascular Health Study Cohort (2017) (15)
The question of a link between insulin-like growth factor physiology and neoplasia. (2000) (14)
Racial variation in umbilical cord blood sex steroid hormones and the insulin-like growth factor axis in African-American and white female neonates (2012) (14)
A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction among Individuals with History of Colorectal Adenomas and Elevated Body Mass Index (2019) (14)
The International Study of Insulin and Cancer (2010) (14)
A prospective study of insulin-like growth factor 1, its binding protein 3, and risk of endometriosis. (2015) (13)
Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes (2017) (13)
Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth (2014) (13)
NCIC-CTG MA14 Trial: Tamoxifen (tam) vs. tam + octreotide (oct) for adjuvant treatment of stage I or II postmenopausal breast cancer (2008) (13)
Menstrual cycle characteristics and steroid hormone, prolactin, and growth factor levels in premenopausal women (2017) (13)
Insulin-like growth factors and liver cancer risk in male smokers (2010) (13)
Competing risks of death in younger and older postmenopausal breast cancer patients. (2014) (13)
Binding between Insulin-like Growth Factor 1 and Insulin-like Growth Factor-binding Protein 3 Is Not Influenced by Glucose or 2-Deoxy-d-glucose (2011) (12)
Enhancement of the anti-neoplastic effects of tamoxifen by somatostatin analogues. (1996) (12)
Fasting insulin and endogenous hormones in relation to premenopausal breast density (Canada) (2014) (12)
Regulation of IGFBP-3 expression in breast cancer cells and uterus by estradiol and antiestrogens: correlations with effects on proliferation: a review. (1995) (12)
The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF‐I, IGF‐II, IGFBP‐1, IGFBP‐2 and IGFBP‐3 in a pooled analysis of 16,024 men from 22 studies (2019) (12)
Exercise Does Not Counteract the Effects of a “Westernized” Diet on Prostate Cancer Xenografts (2013) (12)
Pharmacodynamic properties of the anti-IGF-IR monoclonal antibody CP-751,871 in cancer patients (2007) (12)
Modulation of transforming growth factor beta1 gene expression in the mammary gland by insulin-like growth factor I and octreotide. (2000) (11)
Oncogenic kinases and perturbations in protein synthesis machinery and energetics in neoplasia (2018) (11)
In-vitro fertilisation and family history of breast cancer (1994) (11)
STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer (2021) (11)
Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer (2019) (11)
Pregnancy-dependent growth of mammary tumors is associated with overexpression of insulin-like growth factor II. (1996) (11)
The role of GSK3 in metabolic pathway perturbations in cancer. (2021) (10)
IGF 2 increases de novo steroidogenesis in prostate cancer cells (2013) (10)
Interplay between ShcA Signaling and PGC-1α Triggers Targetable Metabolic Vulnerabilities in Breast Cancer. (2018) (10)
Correlation of plasma levels of free insulin-like growth factor 1 and clinical benefit of the IGF-IR inhibitor figitumumab (CP- 751, 871). (2016) (10)
Safety and tolerability of the anti-IGF-I receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in patients with advanced solid tumors (2007) (10)
Energy metabolism, cancer risk, and cancer prevention. (2009) (10)
Molecular bases for sensitivity to figitumumab (CP-751,871) in NSCLC. (2016) (10)
Stimulation of MC38 tumor growth by insulin analog X10 involves the serine synthesis pathway. (2012) (10)
Intense exercise for survival among men with metastatic castrate-resistant prostate cancer (INTERVAL – MCRPC): A Movember funded multicenter, randomized, controlled phase III study. (2016) (10)
Metformin and Hepatic Carcinogenesis (2012) (9)
Serum insulin‐like growth factor (IGF)‐I and IGF binding protein‐3 in relation to terminal duct lobular unit involution of the normal breast in Caucasian and African American women: The Susan G. Komen Tissue Bank (2018) (9)
Influence of Fasting Status and Sample Preparation on Metabolic Biomarker Measurements in Postmenopausal Women (2016) (9)
Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin (2021) (9)
The Association Between IGF-I and IGFBP-3 and Incident Diabetes in an Older Population of Men and Women in the Cardiovascular Health Study (2017) (9)
Metformin increases 18F-FDG flux and inhibits fatty acid oxidation at clinical doses in breast cancer: Results of a phase 0 clinical trial (2016) (9)
Regression of DMBA-induced breast carcinoma following ovariectomy is associated with increased expression of genes encoding insulin-like growth factor binding proteins. (1999) (9)
Simultaneous Extraction of RNA and Metabolites from Single Kidney Tissue Specimens for Combined Transcriptomic and Metabolomic Profiling. (2018) (9)
Circulating resistin levels and risk of multiple myeloma in three prospective cohorts (2017) (9)
Insulin-like growth factor 1 receptor stabilizes the ETV6–NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation (2018) (9)
Serum transforming growth factor-β1 and risk of pancreatic cancer in three prospective cohort studies (2014) (9)
Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial (2020) (9)
Stabilization of mammary-derived growth inhibitor messenger RNA by antiestrogens. (1997) (9)
Serum C-peptide, Total and High Molecular Weight Adiponectin, and Pancreatic Cancer: Do Associations Differ by Smoking? (2017) (8)
Erratum: Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab (British Journal of Cancer (2011) 104 (68-74) DOI: 10.1038/sj.bjc.6605972) (2012) (8)
Effects of Adiposity and Exercise on Breast Tissue and Systemic Metabo-Inflammatory Factors in Women at High Risk or Diagnosed with Breast Cancer (2021) (8)
A phase II study of preoperative figitumumab (F) in patients (pts) with localized prostate cancer (PCa). (2010) (7)
Associations between time spent sitting and cancer-related biomarkers in postmenopausal women: an exploration of effect modifiers (2014) (7)
Final results of a phase II study of neoadjuvant metformin in prostatic carcinoma. (2013) (7)
Metformin-induced reductions in tumor growth involves modulation of the gut microbiome (2022) (7)
Macronutrient Intake and Cancer: How Does Dietary Restriction Influence Tumor Growth and Why Should We Care? (2009) (7)
Cancer Immunoprevention: A Case Report Raising the Possibility of “Immuno-interception” (2020) (7)
Metformin's potential in oncology. (2013) (6)
The influence of growth hormone/insulin-like growth factor deficiency on prostatic dysplasia in pbARR2-Cre, PTEN knockout mice (2013) (6)
Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer: efficacy with minimal gastrointestinal toxicity and alopecia (2008) (6)
Use of elevated bone turnover to predict bone metastasis (2008) (6)
Prediagnostic plasma C-peptide levels and prostate cancer incidence and survival. (2006) (6)
Plasma Insulin-Like Growth Factor 1 and Binding-Protein 3 and Risk of Myocardial Infarction in Women : A Prospective Study (2008) (6)
Subclinical hypothyroidism and the risk of cancer incidence and cancer mortality: a systematic review (2020) (6)
Advances in Brief Silibinin UpRegulates Insulin-like Growth Factor-Binding Protein 3 Expression and Inhibits Proliferation of Androgen-independent Prostate Cancer Cells 1 (2000) (6)
A phenotype of IGFBP‐3 knockout mice revealed by dextran sulfate‐induced colitis (2017) (5)
The NCIC CTG MA.14 experience with the gallbladder toxicity of octreotide pamoate (oncolar) in a postmenopausal patient population undergoing adjuvant treatment for stage 1-3 breast cancer (2002) (5)
Tamoxifen versus tamoxifen plus octreotide LAR as adjuvant therapy for early-stage breast cancer in postmenopausal women: Update of NCIC CTG MA14 trial. (2010) (5)
Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial. (2021) (5)
Agreement between circulating IGF-I, IGFBP-1 and IGFBP-3 levels measured by current assays versus unavailable assays previously used in epidemiological studies. (2016) (5)
The influence of growth hormone/insulin-like growth factor deficiency on prostatic dysplasia in pbARR2-cre PTEN knockout mice. (2012) (5)
Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations (2021) (5)
Phase 1 Dose Escalation Study of the Monoclonal Antibody Against the Insulin Like Growth Factor I Receptor CP-751,871 in Patients with Multiple Myeloma. (2007) (5)
Prediagnosis Circulating Insulin-Like Growth Factors and Pancreatic Cancer Survival (2017) (4)
Insulin-like growth factor-l and risk of breast cancer (1998) (4)
Plasma Biomarkers of Insulin and the Insulin-like Growth Factor Axis, and Risk of Colorectal Adenoma and Serrated Polyp (2019) (4)
Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis (2022) (4)
Overexpression of insulin-like growth factor binding protein 4 (IGFBP-4) in MCF-7 breast cancer cells is associated with reduced responsiveness to insulin-like growth factors in vitro and reduced tumour growth in vivo. (1997) (4)
Germ-Line BRCA 1 Mutation Is an Adverse Prognostic Factor in Ashkenazi Jewish Women with Breast Cancer 1 (2005) (4)
Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29 (2015) (4)
Relationship of circulating insulin-like growth factor-I and binding proteins 1–7 with mammographic density among women undergoing image-guided diagnostic breast biopsy (2019) (4)
Insulin and insulin-like growth factor signalling in neoplasia (Erratum) (2009) (4)
High-fat Diet Accelerates Carcinogenesis in a Mouse Model of Barrett’s Esophagus via IL8 and Alterations to the Gut Microbiome (2019) (4)
Diet boosts the effectiveness of a cancer drug (2018) (4)
Insulin-like growth factors and neoplasia. (2004) (3)
Metformin and biomarkers relevant to neoplasia in nondiabetic patients. (2013) (3)
Abstract A21: A Phase IIa trial of metformin for colorectal cancer risk reduction among patients with a history of colorectal adenomas and elevated body mass index (2015) (3)
A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21). (2013) (3)
Biological foundation of breast cancer prevention strategies (2002) (3)
Abstract PD5-05: Metabolic obesity, adipose inflammation and aromatase: Potential drivers of breast cancer risk in women with normal body mass index (2017) (3)
Insulin-like growth factor-1 , insulin-like growth factor binding protein-3 and lobule type in the Nurses ' Health Study (2012) (3)
IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405 (2020) (3)
Variant NKX3.1 and Serum IGF-1: Investigation of Interaction in Prostate Cancer. (2013) (3)
Interferon-induced modulation of epidermal growth factor-stimulated growth of a human breast tumor cell line. (1991) (3)
Pre- and Postoperative Circulating IGF-I, IGFBP-3, and IGFBP-7 Levels in Relation to Endocrine Treatment and Breast Cancer Recurrence: A Nested Case-Control Study (2021) (3)
Potential role for somatostatin analogues in breast cancer: rationale and description of an ongoing trial. (1992) (3)
A mathematical model describing consequences of abnormally high levels of epidermal growth factor receptor on the proliferation of neoplastic cells. (1991) (3)
Common genetic variation in IGF 1 , IGFBP-1 , and IGFBP-3 in relation to mammographic density : a cross-sectional study (2016) (3)
Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance). (2017) (3)
Insulin-like growth factor-3 knockout mice are resistant to experimental dextran sulfate sodium colitis. (2016) (3)
Pilot Study Assessing Tolerability and Metabolic Effects of Metformin in Patients With Li-Fraumeni Syndrome. (2020) (3)
Genitourinary tumors, prostate (2012) (3)
Androgen deprivation therapy and the risk of colorectal cancer in patients with prostate cancer (2013) (3)
Circulating IGF-axis protein levels and their relation with levels of plasma adipocytokines and macronutrient consumption in women. (2014) (3)
Serological Markers for the Detection of Prostate Cancer Comprehensive Assessment of Candidate Genes (2003) (3)
Aging, IGF‐1, and diet (2009) (2)
Abstract 2795: Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (2010) (2)
Multicenter, randomized phase II trial of physical activity (PA), metformin (Met), or the combination on metabolic biomarkers in stage I-III colorectal (CRC) and breast cancer (BC) survivors. (2017) (2)
Serum Insulin-like Growth Factor (IGF) and IGF-binding Protein Levels and Risk of Lung Cancer (2002) (2)
Reply: ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’ (2011) (2)
A NO CARBOHYDRATE DIET SIGNIFICANTLY PROLONGS SURVIVAL IN A PROSTATE CANCER XENOGRAFT MODEL VIA IGF-1 AND GLOBAL GENE EXPRESSION CHANGES (2009) (2)
Impact of a change of body mass index (BMI) on outcome following adjuvant endocrine therapy, chemotherapy, or trastuzumab for breast cancer. (2011) (2)
Serum Insulin-like Growth Factor I : Tumor Marker or Etiologic Factor ? (2003) (2)
Randomized trials of adjuvant tamoxifen versus tamoxifen and octreotide LAR in early-stage breast cancer: NCIC CTG MA.14 and NSABP B-29. (2012) (2)
Utilizing metformin to enhance the efficacy of androgen-deprivation therapy in the treatment of prostate cancer. (2011) (2)
Blood Biomarkers Reflect the Effects of Obesity and Inflammation on the Human Breast Transcriptome. (2021) (2)
Hypoxia-Inducible Factor-1a (HIF-1a)Gene Polymorphisms,Circulating Insulin-LikeGrowth Factor Binding Protein (IGFBP)-3 Levels and ProstateCancer (2007) (2)
Serum insulin-like growth factor ( IGF )-I and IGF binding protein-3 in relation to terminal duct lobular unit involution of the normal breast in Caucasian and African American women : The (2018) (2)
Measurement of baseline serum SDF-1 levels as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer. (2011) (2)
Therapeutic Implications of Recent Growth Factor Research (1991) (2)
Dual effects of metformin on breast cancer proliferation in a randomized trial. (2012) (2)
Energy balance at the organism and cellular level: effects of biguanides (2014) (2)
Similarity of Serum and Plasma Insulin-like Growth Factor Concentrations (2015) (2)
A Phase 2 Pharmacodynamic Study of Pre-operative Figitumumab in Patients with Localized Prostate Cancer (2012) (2)
Abstract CT-04: A phase II study of neoadjuvant metformin in prostatic carcinoma (2012) (2)
Direct effects of tamoxifen on growth hormone secretion by pituitary cells by pituitary cells in vivo (1992) (2)
Circulating Insulin-Like Growth Factor 1–Related Biomarkers and Risk of Lethal Prostate Cancer (2021) (2)
Abstract 29: Design of a phase I chemoprevention study of metformin and Li-Fraumeni syndrome (LFS) (2014) (2)
Aspirin use in prostate cancer and the risk of death and metastasis. (2013) (2)
S9 Biology of breast cancer risk and prognosis (1998) (2)
1006 The anti-IGF-IR antibody figitumumab (CP-751,871) is active in patients with lung adenocarcinoma undergoing epithelial-tomesenchymal transition (2009) (1)
BR Co-targeting HER 2 / ErbB 2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER 2-overexpressing breast cancer cells (2002) (1)
737 UTILIZING METFORMIN AS A RADIOSENSITIZING AGENT IN THE TREATMENT OF PROSTATE CANCER (2011) (1)
The Use ofMetformin and the Incidence of Lung Cancer in PatientsWith Type 2 Diabetes (2012) (1)
Obesity, patient characteristics, and TIMP-1: Effects on non-bone RFS in NCIC CTG MA.14. (2010) (1)
Advances in Brief Vitamin D Receptor Gene Polymorphisms , Insulin-like Growth Factors , and Prostate Cancer Risk : A Population-based Case-Control Study in China (2001) (1)
Circulating leptin and risk of pancreatic cancer: a pooled analysis of three cohorts (LB369) (2014) (1)
Translational and HIF1α-dependent metabolic reprograming underpin oncometabolome plasticity and synergy between oncogenic kinase inhibitors and biguanides (2017) (1)
636 Elevated Insulin Can Reduce Effectiveness of PI3K Inhibitors –Rationale for Co-targeting the Insulin Receptor Family and PI3K (2012) (1)
Obesity promotes breast epithelium DNA damage in women carrying a germline mutation in BRCA1 or BRCA2 (2023) (1)
First International Workshop on Growth Hormone, Insulin-like Growth Factors and Neoplasia (2000) (1)
Peptide growth factors and breast cancer treatment: recent translational research. (1996) (1)
Beyond steroid hormones: the new cancer endocrinology. (2010) (1)
Serum Insulin-like Growth Factor ( IGF ) and IGF-binding Protein Levels and Risk of Lung Cancer : A Case-Control Study Nested in the-Carotene and Retinol Efficacy Trial Cohort 1 (2002) (1)
Abstract P3-08-04: Improving sleep to reduce breast cancer risk in shift workers (2016) (1)
The NAMPT Inhibitor FK866 Increases Metformin Sensitivity in Pancreatic Cancer Cells (2022) (1)
Utilizing metformin as a radiosensitizing agent in the treatment of prostate cancer. (2011) (1)
MS3-3: Energy Metabolism in Breast Cancer: Translational Science Insights Relevant to Effects of Diet, Exercise, and Metformin on Risk and Prognosis. (2011) (1)
A Hydride Transfer Complex Reprograms NAD Metabolism Preventing Senescence (2020) (1)
Periprostatic adipose in fl ammation is associated with high-grade prostate cancer (2017) (1)
Cancer Prevention (2018) (1)
Use of serum SDF-1 as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer. (2010) (1)
Prediagnostic use of low‐dose aspirin and risk of incident metastasis and all‐cause mortality among patients with colorectal cancer (2020) (1)
Abstract P4-04-12: Both metabolic syndrome and statin use are more common in women with breast inflammation (2015) (1)
P5-14-01: Differences in Efficacy by Assessment Method: NCIC CTG Adjuvant Breast Cancer Trials MA.5, MA.12, MA.14, MA.21, MA.27 Meta-Analysis. (2011) (1)
565 POSTER Activity of the anti-IGF-IR antibody CP-751,871 in combination with docetaxel as first-line treatment for castration resistant prostate cancer in a randomized Phase II trial (2008) (1)
Abstract 4615: The hyperinsulinemia caused by PI3K inhibitors attenuates their antineoplastic efficacy, but can be minimized by co-administration of metformin. (2013) (1)
P03-26 Insulin-like Growth Factor-II increases de novo steroidogenesis in prostate cancer cells (2012) (1)
Contribution Body Size in Early Life and Adult Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 (2011) (1)
CUOG PHASE II RANDOMIZED STUDY OF CUSTIRSEN (OGX-011) COMBINATION THERAPY IN PATIENTS WITH CASTRATE RESISTANT PROSTATE CANCER (CRPC) WHO RELAPSED ON OR WITHIN SIX MONTHS OF 1ST-LINE DOCETAXEL THERAPY (2009) (1)
Erratum: The human mammary-derived growth inhibitor (MDGI) gene: Genomic structure and mutation analysis in human breast tumors (Genomics (1996) 34:1 (63-68)) (1996) (1)
Dual mode of action of metformin on mitochondrial metabolism (2014) (1)
Re: Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. (1995) (1)
Metformin directly acts on mitochondria to alter cellular bioenergetics (2014) (1)
Abstract P4-09-09: Serum SDF-1: Biomarker of Bone Relapse in the NCIC MA.14 Adjuvant Breast Cancer Trial (2010) (1)
6508 ORAL CP-751, 871, an anti-IGF-IR antibody, in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC): A phase Ib/randomized phase II, non-comparative, open label trial (2007) (1)
Cancer, obesity, and diabetes: TKIs exert multiple effects on glucose homeostasis (2017) (1)
Erratum: Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival (Journal of Experimental Botany (2014) 106:6 (dju085) DOI: 10.1093/jnci/dju085) (2014) (1)
Re: Reversal by transferrin of growth-inhibitory effect of suramin on hormone-refractory human prostate cancer cells. (1995) (1)
1434 ROLE OF METFORMIN IN PROSTATE CANCER PROGRESSION: MECHANISTIC STUDIES IN A XENOGRAFT MODEL (2010) (1)
EPIDERMAL-GROWTH-FACTOR RECEPTORS AND BREAST CANCER (1987) (1)
Differential effects of metformin on breast cancer proliferation according to insulin resistance and tumor subtype in a presurgical trial. (2014) (0)
Anastrozole Is Super ior to Tamoxi fen as Firs t-Line Therapy for Advanced Breast Cancer in Postmenopausal Women : Resul ts of a North American Mult icenter Randomized Tria l (0)
IGF-I-INDUCED ATTENUATION OF THE GROWTH-INHIBITORY ACTIVITY OF TRASTUZUMAB ( HERCEPTIN ) ON SKBR 3 BREAST CANCER CELLS (2003) (0)
Circulating tumor cells expressing the insulin growth factor-1 receptor (IGF-1R): Method of detection, incidence and potential applications (2007) (0)
Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations (2021) (0)
IGF Signaling Is Critical for Growth and Survival of T-Cell Acute Lymphoblastic Leukemia Cells and Is Potentiated by Notch Upregulation of IGF1R (2008) (0)
Body Size and Breast Cancer Prognosis : A Statistical Explanation of the Discrepancies 1 (2006) (0)
RISK OF BREAST CANCER BY INDIVIDUAL INSULIN USE - AN INTERNATIONAL MULTICENTER STUDY Running title Breast cancer and individual insulins (2013) (0)
Abstract 594: Associations of hemoglobin A1c with risk of diabetes-related cancers in the Cancer Prevention Study-II Nutrition Cohort (CPS-II NC) (2019) (0)
Null Results in Brief No Association between Serum Insulin-Like Growth Factor (IGF)-I, IGF-Binding Protein-3, and Lung Cancer Risk (2006) (0)
Com binat ion Chemotherapy With Carboplat in and Bleomycin for Advanced and Recurrent Head and Neck Cancer : A Phase II Study (2006) (0)
Androgen-independent Prostate Cancer Cells Protein 3 Expression and Inhibits Proliferation of Silibinin UpRegulates Insulin-like Growth Factor-Binding Updated (2000) (0)
Abstract 4830: Insulin-like growth factors and kidney cancer risk in men (2010) (0)
P015 Metabolic syndrome and statin use are associated with pro-estrogenic breast inflammation (2015) (0)
Reply to P. Ameri et al (2012) (0)
Diet boosts the effectiveness of a cancer drug (2018) (0)
Metformin inhibits urothelial tumorigenesis in the UPII-mutant Ha-ras transgenic mouse model (2014) (0)
Abstract A35: Associations between time spent sitting and cancer-related biomarkers: An exploration of effect modifiers (2013) (0)
A phase II trial of neoadjuvant metformin in prostatic adenocarcinoma with serum and tissue biomarker evaluation. (2012) (0)
Perspective Perspective on Bhalla et al . , p . 544 Metformin and Hepatic Carcinogenesis (2012) (0)
936 UTILISING METFORMIN AS A RADIOSENSITISING AGENT IN THE TREATMENT OF PROSTATE CANCER (2011) (0)
S9. Energy metabolism, cancer risk, and cancer prevention (2008) (0)
CLINICAL TRIAL OF LYCOPENE IN MEN WITH PROSTATE CANCER (2002) (0)
Molecular Oncology: The insulin–insulin-like growth-factor receptor family as a therapeutic target in oncology (2013) (0)
Abstract SY28-03: Extending the paradigm of hormonal dependency of cancer to account for effects of lifestyle on risk and prognosis (2019) (0)
Independence in Prostate Cancer Models Activity and Accelerates Progression to Androgen Binding Protein-5 Potentiates Insulin-like Growth Factor-I Castration-induced Up-Regulation of Insulin-like Growth Factor (2013) (0)
IGF-related signalling and cancer development (2006) (0)
Title High Sensitivity of an HaRAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with Â 240-Fold Higher Drug Concentration in Urine than Serum Permalink (2016) (0)
CommonPolymorphisms in theAdiponectin and ItsReceptor Genes, Adiponectin Levels and the Risk of Prostate Cancer (2011) (0)
Re: Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. (2003) (0)
Abstract 596: Association between an empirically-derived inflammatory lifestyle score and incident colorectal cancer (2019) (0)
Evidence for a Tumor Promoting Effect of High Fat Diet in the Absence of Hyperinsulinemia in HER2/Neu Mammary Carcinogenesis (2008) (0)
Effect of adjuvant chemotherapy on bone resorption marker beta C-telopeptide (B-CTX) in postmenopausal women. (2016) (0)
Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study (2012) (0)
Insulin, IGFs, and energy balance: Relevance to cancer risk. (2006) (0)
420 IN VIVO CASTRATION-RESISTANT ACCELERATION OF PROSTATE CANCER INHIBITED BY A SMALL MOLECULE INHIBITOR OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR/INSULIN RECEPTOR TYROSINE KINASE (2011) (0)
Reference for patients: valuable or misguided?: Everyone's Guide to Cancer Therapy (1992) (0)
Therapeutics , Targets , and Chemical Biology Serine Deprivation Enhances Antineoplastic Activity of Biguanides (2014) (0)
Abstract 3422: Synthetic lethal siRNA screening reveals novel modifiers of insulin-like growth factor-1 receptor (IGF1R) inhibitor activity in childhood sarcomas (2010) (0)
SAKK 08/15-promet: Multicenter, randomized phase II trial of salvage radiotherapy +/- metformin for patients with prostate cancer after prostatectomy. (2018) (0)
Original Contribution Body Size in Early Life and Adult Levels of Insulin-like Growth Factor 1 and Insulin-like Growth Factor Binding Protein 3 (2011) (0)
Abstract 4071: Association of Plasma Total IGF-I, IGFBP-1 and IGFBP-3 Levels with Incident Coronary Heart Disease and Ischemic Stroke (2006) (0)
tor family targeting agents in breast cancer may be justified. (2012) (0)
Abstract 65: Metformin inhibits in vivo growth of MC38 colon carcinoma in the absence of LKB1 expression (2010) (0)
Effects of KU-55933 on HCT116 p53+/+ and HCT116 p53−/− cells. (2012) (0)
an orthotopic model of murine prostate cancer Exercise modulation of the host-tumor interaction in (2015) (0)
Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer (2021) (0)
Abstract 4420: Elevated glycolytic gene signature in patient-derived neuroendocrine prostate cancer xenograft models and its clinical relevance (2017) (0)
COMMENT ON: MUTAGEN SENSITIVITY AS A RISK FACTOR FOR SECOND MALIGNANT TUMORS FOLLOWING MALIGNANCIES OF THE UPPER AERODIGESTIVE TRACT. AUTHORS' REPLY (1995) (0)
um IGF-I , IGF-II , IGFBP-3 , and IGF-I / IGFBP-3 Molar Ratio Risk of Pancreatic Cancer in the Prostate , Lung , B & P orectal , and Ovarian Cancer Screening Trial (2010) (0)
Genomewide meta-analysis identifies loci associated with IGF-I and IGEBP-3 levels with impact on age-related traits (vol 15, pg 811, 2016) (2017) (0)
The Prostate Effects of Castrationon Insulin Levels andGlucose Tolerance in theMouseDiffer FromThose inMan (2010) (0)
AACR: Insulin Signaling and Cancer Development, Progression (2015) (0)
High-Level IGF1R Expression Is Required for Leukemia Stem Cell Activity In T-ALL and Is Supported by Notch Signaling. (2010) (0)
Individual insulin use and the risk of breast cancer: An international clinical epidemiology study. (2013) (0)
Median WBC and platelet counts 459 Course 1 : Course 2 : Course 3 : Course 4 : Course 5 : Day 1 Day 22 Day 1 Day 22 Day 1 Day 22 Day I Day 22 Day 1 Day (2008) (0)
orectal, and Ovarian Cancer Screening Trial (2010) (0)
Abstract 934: A pooled investigation of circulating adiponectin levels and risk of multiple myeloma (2015) (0)
Case-Control Study in China Factors , and Prostate Cancer Risk : A Population-based Vitamin D Receptor Gene Polymorphisms , Insulin-like Growth (2001) (0)
Abstract PR-04: Interactions between plasma levels of 25-hydroxyvitamin D and insulin-like growth factor (IGF)-1, IGF-binding proteins and C-peptide with risk of colorectal cancer (2010) (0)
Session 3 Preclinical models with relevance to clinical cancer prevention (2004) (0)
A Phase II study of IncelTM (biricodar, VX-710) in combination with paclitaxel in women with advanced breast cancer refractory to paclitaxel (1999) (0)
Abstract PR04: Exogenous estrogen as a mediator of racial differences in insulin-like growth factor-I levels among postmenopausal women (2013) (0)
The Prostate AStudyofHigh-DoseOral Silybin-Phytosome Followedby Prostatectomyin PatientsWith Localized ProstateCancer (2010) (0)
Abstract LB-169: Metformin reduces somatic cell mutation rate by inhibiting mitochondrial ROS production: relevance to cancer prevention (2012) (0)
Abstract CT156: Safety and tolerability of metformin for chemoprevention in Li-Fraumeni syndrome (LFS) (2016) (0)
Abstract 901: Prediagnostic body mass index (BMI), plasma C-peptide levels, and cigarette smoking predict prostate cancer-specific and overall mortality: A 27-year survival analysis in men with PCa (2010) (0)
ISOCALORIC LOW FAT DIET AND PROSTATE CANCER XENOGRAFT PROGRESSION (2010) (0)
Null Results in Brief Dinucleotide Repeat in the Insulin-like Growth Factor-I Gene Is Not Related to Risk of Colorectal Adenoma 1 (2002) (0)
Abstract A106: Coffee consumption and risk of lethal and advanced prostate cancer (2010) (0)
Associations of insulin-like growth factor binding proteins and adiponectin with disease progression and mortality in metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance). (2019) (0)
Abstract LB-28: The IGF/insulin signaling axis TMPRSS2:ERG and prostate cancer survival. (2013) (0)
Abstract A31: eIF4F links translation to energy stress response in cancer (2017) (0)
Dependence of malignant proliferation associated with loss of PTEN on glucose concentration in the hyperglycemic range: Relevance to population studies linking hyperglycemia to unfavorable cancer prognosis. (2009) (0)
Obesity promotes breast epithelium DNA damage in BRCA mutation carriers (2022) (0)
ExerciseDoesNotCounteractthe Effects of a WesternizedDieton ProstateCancerXenografts (2013) (0)
Bioactive Factors in Cow's Milk Raise Levels of Growth Hormone and insulin-Like Growth Factor I in Prepubertal Girls (2006) (0)
Somatostatin analog octreotide (SMS 201–995) enhances endocrine anticancer treatments (1995) (0)
Title: Insulin increases de novo steroidogenesis in prostate cancer cells Running title: Insulin increases steroidogenesis in prostate cancer cells (2011) (0)
Is reducing insulin-resistance relevant to prevent cancer? (2017) (0)
Metformin and the Incidence of Lymphoid Malignancies in Patients with Type 2 Diabetes (2017) (0)
Proceedings of the Society for Experimental PSEBM (2008) (0)
Re: Potential impact of genetic testing on cancer prevention trials, using breast cancer as an example. (1995) (0)
ThePotential RoleofSomatostatin Analogues inBreast Cancer Treatment (1997) (0)
I.4 Effects of anti-oestrogens on insulin-like growth factor (IGF-I) physiology systemically and in the uterus (1998) (0)
Abstract 4501: Energetic risk and prostate cancer-specific and all-cause mortality in two large cohorts of men with localized prostate cancer (2012) (0)
89 EFFECT OF VOLUNTARY WHEEL RUNNING ON GROWTH OF PROSTATE CANCER IN IMMUNOCOMPROMISED AND IMMUNOCOMPETENT MOUSE MODELS (2010) (0)
423 POSTER Metformin is an AMP-kinase dependent growth inhibitor for breast cancer cells (2006) (0)
Abstract A4: C-peptide, mammographic density, and risk of invasive breast cancer (2011) (0)
Metformin Abolishes Increased Tumor FDG Uptake Associated With a High‐Energy Diet (2011) (0)
The influence of growth hormone/insulin-like growth factor deficiency on prostatic dysplasia in pbARR2-cre PTEN knockout mice. (2012) (0)
Advances in Brief Pregnancy-dependent Growth of Mammary Tumors Is Associated with Overexpression of Insulin-like Growth Factor II 1 (2006) (0)
Insulin-Like Growth Factors IGFBP7 Binds to the IGF-1 Receptor and Blocks Its Activation by ` (2013) (0)
Short title: Insulin X10 and the serine synthesis pathway (2012) (0)
Abstract B115: Plasma insulin‐like growth factor 1, binding protein‐3, and risk of prostate cancer: An update from the Health Professional Follow‐up Study 1993–2004 (2010) (0)
Insulin-like growth factor I (IGF-I), IG-binding protein-3 and the risk of colorectal adenoma and cancer in the Nurses' Health Study (2000) (0)
Biomarkers of glucose homeostasis and inflammation with risk of prostate cancer: A case-cohort study. (2022) (0)
937 UTILISING METFORMIN TO ENHANCE THE EFFICACY OF ANDROGEN DEPRIVATION THERAPY IN THE TREATMENT OF PROSTATE CANCER (2011) (0)
Circulating levels of obesity-related markers and risk of renal cell carcinoma in the PLCO cancer screening trial (2017) (0)
Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14 (2016) (0)
Serum Insulin-like Growth Factor I : Tumor Marker or Etiologic Factor ? A Prospective Study of Prostate Cancer among Finnish Men 1 (2003) (0)
Body Size and Breast Cancer Prognosis: A Statistical Explanation of the Discrepancies1 (2006) (0)
740 PROSTATE TUMOR GROWTH IN PBARR2-CRE PTEN KNOCKOUT MICE IS DELAYED IN GH/IGF-I DEFICIENT MICE (2011) (0)
Abstract PL04-01: Metabolic approaches to cancer prevention (2015) (0)
664 UTILISING METFORMIN TO ENHANCE THE EFFICACY OF ANDROGEN DEPRIVATION THERAPY IN THE TREATMENT OF PROSTATE CANCER (2010) (0)
Serum transforming growth factor-β1 and risk of pancreatic cancer in three prospective cohort studies (2014) (0)
Abstract P1-07-13: Prognostic relevance of statistically standardized estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) in tamoxifen(TAM)-treated NCIC CTG MA.14 patients (2012) (0)
The Prostate Androgens , Growth Factors , andRiskof Prostate Cancer : TheMultiethnicCohort (2010) (0)
Metformin mediated AMPK activation inhibits translation initiation in breast cancer cells (2007) (0)
357 IGF-I receptor kinase inhibitor NVP-AEW541-NX-7 abolishes MCF-7 breast cancer cell responsivity to estradiol (2004) (0)
Examination of TIMP-1 Levels and Relapse-Free Survival for Patients in NCIC CTG MA.14 Who Received Adjuvant Tamoxifen +/- Octreotide LAR. (2009) (0)
Contents Vol. 34, 2010 (2010) (0)
Abstract 1799: Utilizing metformin to enhance the efficacy of androgen deprivation therapy in the treatment of prostate cancer (2010) (0)
Investigationand Pancreatic Cancer: A Clue Requiring (2012) (0)
Individualizing interventions for cancer prevention. (2005) (0)
424 POSTER Effects of statins on IGF-IR signaling in normal and transformed breast epithelial cells (2006) (0)
Abstract 2683: Biomarkers of glucose homeostasis and inflammation and risk of prostate cancer: A case-cohort study (2019) (0)
Pioglitazone and the risk of prostate cancer. (2016) (0)
Abstract 1096: Prostate tumor growth in pbARR2-Cre PTEN knockout mice is delayed in GH/IGF-I deficient mice (2011) (0)
Phase II Randomized Clinical Trial of Lycopene Supplementation before Radical Prostatectomy 1 (2001) (0)
425 IGFBP-3 knockout mice develop earlier mammary tumours following dimethylbenz[a]anthracene treatment (2010) (0)
Racial variation in steroid hormone and growth factor concentration: US African-American and white female newborns (2007) (0)
Significance of insulin-like growth factor binding protein-2 in the prognosis of breast cancer and promotion of accelerated growth and chemo-resistance in MDAMB-231 breast cancer model (2005) (0)
Insulin resistance: Influence on cancer risk and cancer prognosis (2007) (0)
Abstract P2-06-03: Obesity is associated with DNA damage in the breast epithelium of BRCA1 and BRCA2 mutation carriers: A role for estrogens & strategies for prevention (2022) (0)
Incidence of periprostatic white adipose tissue inflammation in men with prostate cancer. (2017) (0)
99 UTILIZING METFORMIN TO ENHANCE THE EFFICACY OF ANDROGEN DEPRIVATION THERAPY IN THE TREATMENT OF PROSTATE CANCER (2010) (0)
Abstract A68: Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and lobule type in the Nurses' Health Study II (2011) (0)
Biology of IGF-I: Its interaction with insulin in health and malignant States Novartis Foundation Symposium No. 263 London, 13-16 October 2003 (2003) (0)
Prospective Association of Energy Balance Scores Based on Metabolic Biomarkers with Colorectal Cancer Risk (2020) (0)
Transcriptomic and metabolomic profiling in kidney tissue – a combined approach (2018) (0)
Abstract A36: Serum insulin-like growth factor (IGF)-I and IGF binding protein-3 in relation to terminal duct lobular unit involution in Caucasian and African American women: The Susan G. Komen Tissue Bank (2018) (0)
Cancer controversy (1998) (0)
Metformin in Chemotherapy-Naïve Castration Resistant Prostate Cancer (CRPC): A Multicenter Phase II Trial (SAKK 08/09) (2012) (0)
Abstract 2300: Insulin receptor kinase inhibition is better tolerated than hypoinsulinemia and more effective than metformin in treating breast cancer (2011) (0)
Energy balance and cancer risk at the cellular and whole organism level: modification by metformin (2012) (0)
Abstract LB-323: Self-reported sleep duration and subsequent risk of colorectal cancer in two large cohorts of women and men (2012) (0)
Subject Index Vol. 34, 2010 (2010) (0)
PD3-3-1: A phase Ib/randomized phase II, non-comparative, open label trial of paclitaxel and carboplatin with or without the anti-IGF-IR antibody CP-751,871 as first-line treatment for advanced non-small cell lung cancer (NSCLC) (2007) (0)
Independence in Prostate Cancer Models Factor-I Activity and Accelerates Progression to Androgen Factor Binding Protein-5 Potentiates Insulin-like Growth Castration-induced Up-Regulation of Insulin-like Growth Updated (2000) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Michael N. Pollak?

Michael N. Pollak is affiliated with the following schools:

Michael N. Pollak's Academic­Influence.com Rankings

Michael N. Pollak's Degrees

Why Is Michael N. Pollak Influential?

Michael N. Pollak's Published Works

Published Works

What Schools Are Affiliated With Michael N. Pollak?

Michael N. Pollak's AcademicInfluence.com Rankings